Certain populations of immune monocytes and macrophages may be important targets of mesenchymal stem cell (MSC) therapy in idiopathic pulmonary fibrosis (IPF), according to a study. In an IPF mouse model, into-the-vein MSC treatment appeared to prevent monocytes from becoming a type of macrophage thought to promote the buildup…
News
Black patients with pulmonary fibrosis (PF) are diagnosed around a decade earlier than their white counterparts in the U.S., a new study reports. They also tend to be hospitalized more often and at younger ages compared with white or Hispanic patients, and were significantly younger at time of death,…
Trevi Therapeutics has won approval of its patent application for Haduvio (nalbuphine extended-release tablets), an investigational treatment for chronic cough in people with idiopathic pulmonary fibrosis (IPF). The notice of allowance approving the application was issued on March 7 by the U.S. Patent and Trademark Office. The future…
Being exposed at work to medium or high levels of asbestos is associated with a near double risk of developing idiopathic pulmonary fibrosis (IPF) for cigarette smokers, according to a recent U.K. study involving men. The association between asbestos, smoking, and IPF was especially strong in people with a…
Carestream Health and the Open Source Imaging Consortium (OSIC) are collaborating in the OSIC Pulmonary Understanding Study, dubbed Project OPUS — a pilot study to uncover X-ray markers for the early diagnosis of idiopathic pulmonary fibrosis (IPF). Project OPUS will make use of artificial intelligence, or…
Individuals with idiopathic pulmonary fibrosis (IPF) who experience unintended weight loss are at significantly higher risks of being admitted to the hospital or dying within one year, a Danish study reported. Specifically, IPF patients with unintended weight loss were found to have a nearly 30 times higher risk of…
Nicole Zuraitis is set to perform “Just Like That,” the 2023 Grammy Awards’ Song of the Year, at the 13th edition of “Broadway Belts for PFF!” — a glam affair that’s become the Pulmonary Fibrosis Foundation’s single-largest annual fundraiser — on March 6. Written by Bonnie Raitt, the song…
The California Institute for Regenerative Medicine (CIRM) has awarded Rubedo Life Sciences $1.45 million to develop and study a potentially disease-modifying treatment for idiopathic pulmonary fibrosis (IPF) that targets senescent lung stem cells. The funding will enable the biopharmaceutical company to characterize senescent cells —…
The first patient has been dosed in a Phase 2 clinical trial of bersiporocin, Daewoong Pharmaceutical’s treatment candidate for idiopathic pulmonary fibrosis (IPF). Full patient dosing and initial data from the study are anticipated by 2024, according to Daewoong. “Daewoong Pharmaceutical has set the significant first step to the…
CS Pharmaceuticals (CSP) has entered into an exclusive in-licensing agreement with Daewoong Pharmaceutical to develop and commercialize bersiporocin, an oral experimental anti-fibrotic medication for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases in the greater China region. “This will be the stepping stone towards becoming a game…
